PDF(Pubmed)
Abstract：
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative impact on health and increase morbidity and mortality. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss. Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio-metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies.
摘要：
肥胖是一种具有高患病率和相关合并症的慢性疾病，使其成为全球日益关注的问题。这些合并症包括2型糖尿病，高血压,通气功能障碍,关节病,静脉和淋巴循环疾病，抑郁症,和其他人,对健康产生负面影响，增加发病率和死亡率。GLP-1激动剂,用于治疗2型糖尿病，在临床前和临床研究中已证明可有效促进体重减轻。这篇综述总结了对GLP-1激动剂类主要药物进行的大量研究。概述可实现的最大重量损失。我们的目的是强调GLP-1激动剂在促进体重减轻中的积极作用和主要结果。以及改善高血糖症，胰岛素敏感性，血压,心脏代谢，和肾脏保护。我们强调了这些药物的多效性，连同他们的适应症，禁忌症,糖尿病和非糖尿病患者的预防措施，基于长期随访研究。
